Literature DB >> 3883862

The effect of inhaled leukotriene D4 in humans.

L J Smith, P A Greenberger, R Patterson, R D Krell, P R Bernstein.   

Abstract

Leukotriene D, (LTD4) is a potent bronchoconstrictor that may play an important role in asthma. To better characterize the effect of LTD4 on human airways, normal, rhinitic, and asthmatic subjects underwent inhalation challenge tests with LTD4 and methacholine. In all subjects increasing concentrations of LTD4 produced a parallel decrease in specific airway conductance and flow at 30% of vital capacity measured from a partial forced expiratory maneuver (V30P). These changes occurred independent of any decrease in FEV1 or increase in functional residual capacity. The airway response to LTD4 was maximal within 2 to 3 min, persisted for approximately 30 min, and resolved over 1 to 3 h. Late effects were not seen. Rhinitic subjects were 3 to 5 times (p less than 0.01) and asthmatic subjects were 25 to 100 times (p less than 0.001) more sensitive than were normal subjects to LTD4. All 3 groups of subjects were 250 to 850 times more sensitive to LTD4 than to methacholine. Significant correlations were found between the concentration of LTD4 and the concentration of methacholine that produced a 35% decrease in specific airway conductance (r = 0.874; p less than 0.006) and a 30% decrease in V30P (r = 0.751; p less than 0.04). These results confirm that LTD4 is a potent bronchoconstrictor in humans, with a rapid onset of action and a prolonged effect. In contrast to previous reports, we found that LTD4 has an equal effect on both large and small airways and that both asthmatic and normal subjects have the same degree of increased sensitivity to LTD4 as to methacholine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3883862     DOI: 10.1164/arrd.1985.131.3.368

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

Review 1.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 4.  Exercise-induced bronchospasm in the elite athlete.

Authors:  Kenneth W Rundell; David M Jenkinson
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

5.  Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma.

Authors:  M K Albazzaz; K R Patel
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

6.  The comparative effects of dietary alpha-linolenic acid and fish oil on 4- and 5-series leukotriene formation in vivo.

Authors:  J Whelan; K S Broughton; J E Kinsella
Journal:  Lipids       Date:  1991-02       Impact factor: 1.880

7.  Effect of zileuton on theophylline pharmacokinetics.

Authors:  G R Granneman; R A Braeckman; C S Locke; J H Cavanaugh; L M Dubé; W M Awni
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma.

Authors:  J S Mann; C Robinson; A Q Sheridan; P Clement; M K Bach; S T Holgate
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

9.  Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness.

Authors:  T B Casale; D Wood; H B Richerson; S Trapp; W J Metzger; D Zavala; G W Hunninghake
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

10.  Contrasting effects of allergen challenge on airway responsiveness to cysteinyl leukotriene D(4) and methacholine in mild asthma.

Authors:  R I Ketchell; M D'Amato; M W Jensen; B J O'Connor
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.